An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030000

Enrollment

Unknown

Registered

2020-02-19

Start date

2020-02-16

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia caused by new coronavirus

Interventions

Ganovo / ritonavir group:Ganovo/ ritonavir oral

Pegasys group:Pegasys injection

Novaferon group:Novaferon intramuscular injection+Spray inhalation

Coriolus group:Coriolus oral

Comparator:TCM+Spray inhalation

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years old; 2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 4); 3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days); 4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration; 5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration. 6.Patients who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 =C, AST > 5 times upper limit); 4. Patients with contraindications specified in the instructions of ritonavir tablets; 5. The pregnancy test of female subjects in the screening period was positive; 6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).

Design outcomes

Primary

Measure	Time frame
Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;	—

Secondary

Measure	Time frame
novel coronavirus nucleic acid detection;	—

Countries

China

Contacts

Public ContactHongyi Chen

Nanchang Ninth Hospital

Chenhongyi8660@163.com+86 13807088660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026